Mr Carl H Rosen, MD | |
6373 Brandenburg Rd, Leitchfield, KY 42754-7534 | |
(270) 215-1036 | |
(270) 844-4654 |
Full Name | Mr Carl H Rosen |
---|---|
Gender | Male |
Speciality | Urology |
Location | 6373 Brandenburg Rd, Leitchfield, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316931959 | NPI | - | NPPES |
000000612653 | Other | KY | ANTHEMBCBS |
10810680 | Other | KY | CAQH |
000000476600 | Other | KY | ANTHEM BLUE CROSS AND BLUE SHIELD |
64300205 | Medicaid | KY | |
50023040 | Other | KY | PASSPORT HEALTH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 30020 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Carl H Rosen, MD 6373 Brandenburg Rd, Leitchfield, KY 42754-7534 Ph: (270) 215-1036 | Mr Carl H Rosen, MD 6373 Brandenburg Rd, Leitchfield, KY 42754-7534 Ph: (270) 215-1036 |
News Archive
With the fifth anniversary of the presidential signing of the U.S. Affordable Care Act March 23, faculty experts from DePaul University are available to discuss a range of health care topics including the analysis of health care data, community health, patient experience, communication among health care professionals, interprofessional health care education and the role of nurses and physician assistants.
Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.
Buruli ulcer - one of the most neglected among the NTDs - is a debilitating and stigmatizing disease. Affecting mainly children in West and Central Africa, the chronic disease results in devastating skin lesions and can lead to permanent disfigurement and long-term disabilities.
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
The burden of cancer is on the rise in low- and middle-income countries (LMICs) such as Honduras.
› Verified 5 days ago